Drug intelligence / Profile preview

Hu-rhEGF-rP64k + montelukast

Development stage: Preclinical
Lead developer: Center for Molecular Immunology
Modality: Small Molecules, Vaccines & Immunotherapeutics
Administration: Intramuscular, Oral

Overview

A combination of Hu-rhEGF-rP64k (CimaVax-EGF), a therapeutic cancer vaccine, and montelukast, a leukotriene receptor antagonist. Hu-rhEGF-rP64k is composed of recombinant human EGF (rhEGF) chemically conjugated to recombinant P64K (rP64K) with Montanide ISA51VG as an adjuvant. The vaccine component induces neutralizing antibodies against EGF, preventing it from binding to the EGF receptor and inhibiting cancer cell proliferation.

Other names: CimaVax-EGF + montelukast

Targets

CYSLTR1 (Cysteinyl-leukotriene type 1 receptor)EGFR (Epidermal growth factor receptor)

Beyond the preview

Go deeper on Hu-rhEGF-rP64k + montelukast.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hu-rhEGF-rP64k + montelukast.

Explore the full profile